Half-dose photodynamic therapy for chronic central serous chorioretinopathy evaluated by focal macular electroretinograms

Jpn J Ophthalmol. 2017 May;61(3):260-266. doi: 10.1007/s10384-017-0498-9. Epub 2017 Feb 2.

Abstract

Purpose: To evaluate the effect of half-dose verteporfin photodynamic therapy (hPDT) on the physiology of the macula determined by focal macular electroretinograms (FMERGs) in eyes with chronic central serous chorioretinopathy (CSC).

Methods: Fourteen eyes of 13 patients with chronic CSC were treated with hPDT. The best-corrected visual acuity (BCVA) was measured, and optical coherence tomography (OCT) and FMERGs were performed at the baseline, and at 4 days, 1, 3, 6, and 12 months after the hPDT.

Results: The subreitnal fluid was resolved in 12 of the 14 eyes after the hPDT. The amplitude of the a-wave at 12 months was significantly increased by 1.28 times over that at the baseline. The amplitude of the b-wave was also increased but not significantly (P = 0.055). The implicit time of the a-wave was significantly reduced at 6 months, and that of the b-wave at 3 months. The amplitudes of the oscillatory potentials did not change significantly during the 12-month follow-up period.

Conclusions: hPDT led to an improvement in the FMERGs for at least 12 months without a transient depression of the FMERGs in eyes with chronic CSC. hPDT can be used safely to treat eyes with CSC.

Keywords: CSC; Focal macular ERG; Half-dose PDT; Retina.

MeSH terms

  • Adult
  • Aged
  • Central Serous Chorioretinopathy / diagnosis
  • Central Serous Chorioretinopathy / drug therapy*
  • Central Serous Chorioretinopathy / physiopathology
  • Dose-Response Relationship, Drug
  • Electroretinography / methods*
  • Female
  • Fluorescein Angiography / methods
  • Follow-Up Studies
  • Fundus Oculi
  • Humans
  • Injections, Intravenous
  • Macula Lutea / pathology
  • Macula Lutea / physiopathology*
  • Male
  • Middle Aged
  • Photochemotherapy / methods*
  • Photosensitizing Agents / administration & dosage
  • Porphyrins / administration & dosage*
  • Retrospective Studies
  • Time Factors
  • Tomography, Optical Coherence / methods
  • Treatment Outcome
  • Verteporfin
  • Visual Acuity*

Substances

  • Photosensitizing Agents
  • Porphyrins
  • Verteporfin